Advertisement

La chimiothérapie des rechutes au-delà de six mois

  • J.-F. Geay
  • I. Ray-Coquard
  • É. Pujade-Lauraine
Part of the Abord clinique book series (ONCOLPRAT)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Ries LAG, Eisner MP, Kosary CL et al. (eds) (2002) SEER Cancer Statistics Review, 1973–1999. Bethesda, Md: National Cancer Institute Available at: http://seer.cancer.gov/csr/ 1973_1999/. Accessed March 24, 2002Google Scholar
  2. 2.
    Runnebaum IB, Stickeler E (2001) Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 127: 73–9CrossRefPubMedGoogle Scholar
  3. 3.
    Yancik R (1993) Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71(2 suppl): 517–23PubMedGoogle Scholar
  4. 4.
    Omura GA, Brady MF, Homesley HD et al. (1991) Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 9: 1138–50PubMedGoogle Scholar
  5. 5.
    Thigpen T, Brady MF, Omura GA et al. (1993) Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 71(2 suppl): 606–14PubMedGoogle Scholar
  6. 6.
    Rubin SC, Benjamin I, Behbakht K et al. (1996) Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335: 1413–6CrossRefPubMedGoogle Scholar
  7. 7.
    McGuire WP, Hoskins WJ, Brady MF et al. (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1–6CrossRefPubMedGoogle Scholar
  8. 8.
    Piccart MJ, Bertelsen K, James K et al. (2000) Randomized intergroup trial of cisplatinpaclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699–708CrossRefPubMedGoogle Scholar
  9. 9.
    Neijt JP, Engelholm SA, Tuxen MK et al. (2000) Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18: 3084–92PubMedGoogle Scholar
  10. 10.
    du Bois A, Lueck HJ, Meier W et al. (1999) Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group trial. Proc Am Soc Clin Oncol 18: Abstract 1374Google Scholar
  11. 11.
    Ozols R, Bundy B, Fowler J (1999) Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 158). Proc Am Soc Clin Oncol. 18: 356a. Abstract 1373Google Scholar
  12. 12.
    McGuire WP, Brady MF, Ozols RF (1999) The Gynecologic Oncology Group experience in ovarian cancer. Ann Oncol 10: 29–34CrossRefPubMedGoogle Scholar
  13. 13.
    Piccart M, Bertelsen K, Stuart G et al. (2002) Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin (TP) regimen over the cyclophosphamide-cisplatin (CP) combination in advanced ovarian cancer (AOC). Ann Oncol 13: 109. Abstract 395Google Scholar
  14. 14.
    Therasse P, Arbuck SG, Eisenhauer EA et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205–16CrossRefPubMedGoogle Scholar
  15. 15.
    Vergote I, Rustin GJ, Eisenhauer EA et al. (2000) Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup. J Natl Cancer Inst 92: 1534–5CrossRefPubMedGoogle Scholar
  16. 16.
    Markman M, Rothman R, Hakes T et al. (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389–93PubMedGoogle Scholar
  17. 17.
    Pujade-Lauraine E, Paraiso D, Cure H et al. (2002) Predicting the effectiveness of chemotherapy (Cx) in patients with recurrent ovarian cancer (ROC): a GINECO study. Proc Am Soc Clin Oncol 21: Abstract 829Google Scholar
  18. 18.
    Blackledge G, Lawton F, Redman C et al. (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: Implications for patient treatment and the design of phase II trials. Br J Cancer 9: 650–3Google Scholar
  19. 19.
    Gershenson DM, Kanavagh JJ, Copeland LJ et al. (1989) Re-treatment of patients with recurrent epithelial ovarian cancer with Cisplatin-based chemotherapy. Obstet Gynecol 73: 298–801Google Scholar
  20. 20.
    Seltzer V, Vogl S, Kaplan B (1985) Recurrent ovarian carcinoma: retreatment using combination chemotherapy including cis-diaminechloroplatinum in patients previous responding to this agent. Gynecol Oncol 21: 167–76CrossRefGoogle Scholar
  21. 21.
    van der Burg MEL, Hoff AM, van Lent M et al. (1991) Carboplatin and Cyclophosphamide salvage therapy for ovarian cancer patients relapsing after Cisplatin combination chemotherapy. Eur J Cancer 27: 248–50PubMedGoogle Scholar
  22. 22.
    Pujade-Lauraine E, Guastalla JP, Weber B et al. (1997) Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Group des Investigateurs Nationaux pour L’Etude des Cancers Ovariens (GINECO) phase II study. Semin Oncol 24: 15–30Google Scholar
  23. 23.
    Rose PG, Fusco N, Fluellen L et al. (1998) Second-line therapy with paclitaxel and Carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian and peritoneal carcinoma. J Clin Oncol 16: 1494–7PubMedGoogle Scholar
  24. 24.
    Cantu MG, Buda A, Parma G et al. (2002) Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20: 1232–7CrossRefPubMedGoogle Scholar
  25. 25.
    Parmar MK, Ledermann JA, Colombo N et al. (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099–106PubMedGoogle Scholar
  26. 26.
    Pfisterer J, Vergote I, Du Bois A et al. (2005) AGO-OVAR, NCIC CTG & EORTC GCG. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 15Suppl 1: 36–41PubMedGoogle Scholar
  27. 27.
    Ferrero JM, Weber B, Lepille D et al. (2004) Caelyx (Ca) and Carboplatin (Pa) in patients with advanced ovarian cancer in late relapse (> 6 months) (AOCLR): Late results of a GINECO phase II trial. Proc Am Soc Clin Oncol 23 (abstr 454)Google Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • J.-F. Geay
  • I. Ray-Coquard
  • É. Pujade-Lauraine

There are no affiliations available

Personalised recommendations